Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice

作者：Ai Ding^*; Baez Juan M; Jiang Hongfeng; Conlon Donna M; Hernandez Ono Antonio; Frank Kamenetsky Maria; Milstein Stuart; Fitzgerald Kevin; Murphy Andrew J; Woo Connie W; Strong Alanna; Gin**erg Henry N; Tabas Ira; Rader Daniel J; Tall Alan R

来源：Journal of Clinical Investigation, 2012, 122(5): 1677-1687.

DOI：10.1172/JCI61248

Recent GWAS have identified SNPs at a human chromosoml locus associated with coronary artery disease risk and LDL cholesterol levels. The SNPs are also associated with altered expression of hepatic sortilin-1 (SORT1), which encodes a protein thought to be involved in apoB trafficking and degradation. Here, we investigated the regulation of Sortl expression in mouse models of obesity. Sortl expression was markedly repressed in both genetic (ob/ob) and high-fat diet models of obesity; restoration of hepatic sortilin-1 levels resulted in reduced triglyceride and apoB secretion. Mouse models of obesity also exhibit increased hepatic activity of mammalian target of rapamycin complex 1 (mTORC1) and ER stress, and we found that administration of the mTOR inhibitor rapasnycin to ob/ob mice reduced ER stress and increased hepatic sortilin-1 levels. Conversely, genetically increased hepatic mTORC1 activity was associated with repressed Sort1 and increased apoB secretion. Treating WT mice with the ER stressor tunicamycin led to marked repression of hepatic sortilin-1 expression, while administration of the chemical chaperone PBA to ob/ob mice led to amelioration of ER stress, increased sortilin-1 expression, and reduced apoB and triglyceride secretion. Moreover, the ER stress target Atf3 acted at the SORT1 promoter region as a transcriptional repressor, whereas knockdown of Atf3 mRNA in ob/ob mice led to increased hepatic sortilin-1 levels and decreased apoB and triglyceride secretion. Thus, in mouse models of obesity, induction of mTORC1 and ER stress led to repression of hepatic Sortl and increased VLDL secretion via Atf3. This pathway may contribute to dyslipidemia in metabolic disease.

• 出版日期2012-5